Episurf Medical publishes prospectus regarding the admission to trading of new shares of series B on Nasdaq Stockholm

Episurf Medical AB (publ) (“Episurf Medical” or the “Company”) has on 14 October 2021, based on the authorisation granted by the Annual General Meeting on 10 May 2021, carried out a directed issue of 44,408,108 new shares of series B (the “Share Issue”). The Share Issue was directed mainly to Health Runner AB, a company controlled by Ilija Batljan, and in addition to a limited number of institutional investors.

The Company has prepared a prospectus regarding the Company’s application for admission to trading of the new shares of series B on Nasdaq Stockholm, which has today been approved and registered with the Swedish Financial Supervisory Authority in accordance with Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017. The prospectus is available at the Company’s website (www.episurf.com) and will also be available via the Swedish Financial Supervisory Authority’s website (www.fi.se). The new shares of series B are expected to be admitted to trading on Nasdaq Stockholm on or around 30 November 2021.

Zonda Partners AB has acted as financial advisor and Hannes Snellman Attorneys Ltd has acted as legal advisor in connection with the Share Issue. Eminova Fondkommission AB is settlement agent for the Share Issue.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

Veronica Wallin, CFO, Episurf Medical
Tel:+46 (0) 700 37 48 95
Email: veronica.wallin@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

Important information

This press release does not constitute an offer to, or an invitation to, acquire or subscribe for any securities in Episurf Medical in any jurisdiction, neither from Episurf Medical, Zonda Partners AB or anyone else. Copies of this press release will not be produced and may not be distributed or sent to the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa or any other jurisdiction where such distribution would be illegal or require registration or other action. The recipient of this press release is responsible for using this press release and the information herein in accordance with applicable rules in each jurisdiction.

This press release is not a prospectus for the purposes of Regulation (EU) 2017/1129 (the “Prospectus Regulation”) and has not been approved by any regulatory authority in any jurisdiction. Episurf Medical has not authorised any offer to the public of shares or other securities in any member state of the EEA.

This press release and the information contained in the press release may not be distributed in or to the United States. This press release does not constitute an offer to acquire securities in the United States. Securities referred to herein have not been registered and will not be registered in accordance with the US Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States without being registered, subject to an exception to, or refers to a transaction that is not subject to registration under the Securities Act. No offer will be made to the public in the United States to acquire the securities mentioned here.

This press release may contain certain forward-looking information which reflect Episurf Medical's current view of future events and financial and operational developments. Words such as "intends", "estimates", "expects", "may", "plans", "deems", "believes", "assesses", and other similar expressions which imply indications or predictions regarding future developments or trends, and which are not based on historical facts, constitute forward-looking information. Forward-looking information is by nature affiliated with known and unknown risks and uncertainties since it is dependent on future events and circumstances. Forward-looking information does not constitute any guarantee regarding future results or development and the actual outcome may materially differ from forward-looking information. The information, assessments and forward-looking statements in this press release are only relevant as of the date of this press release and may change without notice.